1
|
Mutations of p53 gene in canine sweat gland carcinomas probably associated with UV radiation. J Vet Res 2021; 65:519-526. [PMID: 35112008 PMCID: PMC8775725 DOI: 10.2478/jvetres-2021-0070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 12/09/2021] [Indexed: 11/20/2022] Open
Abstract
Abstract
Introduction
Apocrine sweat gland carcinomas (ASGCs) are rare malignant skin tumours in dogs and humans. The literature published so far focuses mostly on the clinico-epidemiological aspect of these tumours, but little is known about their pathogenesis. In this study we aimed to determine whether the p53 gene is involved in the carcinogenesis of the apocrine sweat gland in dogs and whether ultraviolet radiation (UV) is related to it.
Material and Methods
Forty canine ASGCs were submitted to laser capture microdissection to isolate neoplastic cells, from which DNA was subsequently extracted. PCR amplification and sequencing of p53 exons 2–8 was then performed, followed by computer analysis of the obtained sequences.
Results
Sixteen mutations within the p53 gene were found in 13 tumours. The mutations involved C → T, T → C, G → A, and CC → TT transitions, C → G transversion and adenine deletion, which are gene alteration types known to be related to UV radiation in the process of skin carcinogenesis in humans. Six of the thirteen tumour cases displayed the C → T transitions in the same location in exon 4 and three of the thirteen cases displayed T → C in the same location in exon 5.
Conclusion
The results of the present study indicate both the participation of the p53 gene and the influence of UV radiation in the formation of ASGCs in dogs.
Collapse
|
2
|
Wang X, Priya Veeraraghavan V, Krishna Mohan S, Lv F. Anticancer and immunomodulatory effect of rhaponticin on Benzo(a)Pyrene-induced lung carcinogenesis and induction of apoptosis in A549 cells. Saudi J Biol Sci 2021; 28:4522-4531. [PMID: 34354438 PMCID: PMC8324936 DOI: 10.1016/j.sjbs.2021.04.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 04/07/2021] [Accepted: 04/18/2021] [Indexed: 01/14/2023] Open
Abstract
In worldwide, one of the most important cancer-related death is lung cancer. Also has the highest mortality rate between various cancer types. The count of lung cancer occurrence is increasing with an increased frequency by smoking. Proficient chemoprevention approaches are needed to prevent the occurrence of lung cancer. Therefore, the aim of this exploration is to determine the therapeutic impact on the immune modulatory effect of rhaponticin on lung tumorigenesis in vivo and in vitro cytotoxicity effect in A549 cells of human lung cancer. Lung cancer tumorigenesis in mice was challenged with benzo(a)pyrene (BaP) with 50 mg/kg bodyweight (b.wt) as oral administration for 6 weeks (two times/week). Rhaponticin were given orally 30 mg/kg b.wt (two times/week) in BaP induced mice from 12 weeks to 18 weeks. After treatment completes, the body weight was measured and then blood, lung tissue was collected for various parameters detection. The results evidenced that BaP induced mice decreased the bodyweight, increased lung weight, increased tumor markers (AHH, CEA and LDH), and increased the proinflammatory cytokines. The enzyme catalase, superoxide dismutase activity was decreased and increased lipid peroxidation in immune comprising cells compared with the control cells. Moreover, rhaponticin treatment improves in chemical assays and also the histopathological alteration of lung tissues. The present findings provide evidence about the therapeutic potentials of rhaponticin against BaP triggered lung tumorigenesis.
Collapse
Affiliation(s)
- Xiaodong Wang
- Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China
| | - Vishnu Priya Veeraraghavan
- Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600 077, India
| | - Surapaneni Krishna Mohan
- Department of Biochemistry, Department of Clinical Skills & Simulation and Department of Research, Panimalar Medical College Hospital & Research Institute, Varadharajapuram, Poonamallee, Chennai 600 123, India
| | - Feng Lv
- Department of Thoracic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China
- Corresponding author.
| |
Collapse
|
3
|
Schenk EL, Patil T, Pacheco J, Bunn PA. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist 2021; 26:e454-e472. [PMID: 33179378 PMCID: PMC7930417 DOI: 10.1002/onco.13590] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Accepted: 11/05/2020] [Indexed: 12/13/2022] Open
Abstract
Lung cancer is the leading cause of cancer death in both males and females in the U.S. and worldwide. Owing to advances in prevention, screening/early detection, and therapy, lung cancer mortality rates are decreasing and survival rates are increasing. These innovations are based on scientific discoveries in imaging, diagnostics, genomics, molecular therapy, and immunotherapy. Outcomes have improved in all histologies and stages. This review provides information on the clinical implications of these innovations that are practical for the practicing physicians, especially oncologists of all specialities who diagnose and treat patients with lung cancer. IMPLICATIONS FOR PRACTICE: Lung cancer survival rates have improved because of new prevention, screening, and therapy methods. This work provides a review of current standards for each of these areas, including targeted and immunotherapies. Treatment recommendations are provided for all stages of lung cancer.
Collapse
Affiliation(s)
- Erin L. Schenk
- Division of Medical Oncology, University of Colorado Cancer CenterAuroraColoradoUSA
| | - Tejas Patil
- Division of Medical Oncology, University of Colorado Cancer CenterAuroraColoradoUSA
| | - Jose Pacheco
- Division of Medical Oncology, University of Colorado Cancer CenterAuroraColoradoUSA
| | - Paul A. Bunn
- Division of Medical Oncology, University of Colorado Cancer CenterAuroraColoradoUSA
| |
Collapse
|
4
|
Ramelow J, Brooks CD, Gao L, Almiman AA, Williams TM, Villalona-Calero MA, Duan W. The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer 2020; 20:738. [PMID: 32770960 PMCID: PMC7414707 DOI: 10.1186/s12885-020-07212-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 07/23/2020] [Indexed: 12/25/2022] Open
Abstract
Background Lung cancer is the number one cancer killer worldwide. A major drawback in the lung cancer treatment field is the lack of realistic mouse models that replicate the complexity of human malignancy and immune contexture within the tumor microenvironment. Such models are urgently needed. Mutations of the tumor protein p53 are among the most common alterations in human lung cancers. Methods Previously, we developed a line of lung cancer mouse model where mutant human TP53-273H is expressed in a lung specific manner in FVB/N background. To investigate whether the human TP53 mutant has a similar oncogenic potential when it is expressed in another strain of mouse, we crossed the FVB/N-SPC-TP53-273H mice to A/J strain and created A/J-SPC-TP53-273H transgenic mice. We then compared lung tumor formation between A/J-SPC-TP53-273H and FVB/N-SPC-TP53-273H. Results We found the TP53-273H mutant gene has a similar oncogenic potential in lung tumor formation in both mice strains, although A/J strain mice have been found to be a highly susceptible strain in terms of carcinogen-induced lung cancer. Both transgenic lines survived more than 18 months and developed age related lung adenocarcinomas. With micro CT imaging, we found the FVB-SPC-TP53-273H mice survived more than 8 weeks after initial detection of lung cancer, providing a sufficient window for evaluating new anti-cancer agents. Conclusions Oncogenic potential of the most common genetic mutation, TP53-273H, in human lung cancer is unique when it is expressed in different strains of mice. Our mouse models are useful tools for testing novel immune checkpoint inhibitors or other therapeutic strategies in the treatment of lung cancer.
Collapse
Affiliation(s)
- Julian Ramelow
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA.,Biomolecular Sciences Institute, The Florida International University, Miami, Florida, 33199, USA.,Biological Sciences, College of Arts, Science and Education, The Florida International University, Miami, Florida, 33199, USA
| | - Christopher D Brooks
- Comprehensive Cancer Center at the Ohio State University College of Medicine, Columbus, OH, 43210, USA
| | - Li Gao
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA
| | - Abeer A Almiman
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA
| | - Terence M Williams
- Comprehensive Cancer Center at the Ohio State University College of Medicine, Columbus, OH, 43210, USA
| | | | - Wenrui Duan
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, Florida, 33199, USA. .,Biomolecular Sciences Institute, The Florida International University, Miami, Florida, 33199, USA. .,Comprehensive Cancer Center at the Ohio State University College of Medicine, Columbus, OH, 43210, USA.
| |
Collapse
|
5
|
Yun BH, Guo J, Bellamri M, Turesky RJ. DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans. MASS SPECTROMETRY REVIEWS 2020; 39:55-82. [PMID: 29889312 PMCID: PMC6289887 DOI: 10.1002/mas.21570] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 04/25/2018] [Indexed: 05/18/2023]
Abstract
Hazardous chemicals in the environment and diet or their electrophilic metabolites can form adducts with genomic DNA, which can lead to mutations and the initiation of cancer. In addition, reactive intermediates can be generated in the body through oxidative stress and damage the genome. The identification and measurement of DNA adducts are required for understanding exposure and the causal role of a genotoxic chemical in cancer risk. Over the past three decades, 32 P-postlabeling, immunoassays, gas chromatography/mass spectrometry, and liquid chromatography/mass spectrometry (LC/MS) methods have been established to assess exposures to chemicals through measurements of DNA adducts. It is now possible to measure some DNA adducts in human biopsy samples, by LC/MS, with as little as several milligrams of tissue. In this review article, we highlight the formation and biological effects of DNA adducts, and highlight our advances in human biomonitoring by mass spectrometric analysis of formalin-fixed paraffin-embedded tissues, untapped biospecimens for carcinogen DNA adduct biomarker research.
Collapse
Affiliation(s)
- Byeong Hwa Yun
- Masonic Cancer Center and Department of Medicinal Chemistry, University of Minnesota, 2231 6 St. SE, Minneapolis, Minnesota, 55455, United States
| | - Jingshu Guo
- Masonic Cancer Center and Department of Medicinal Chemistry, University of Minnesota, 2231 6 St. SE, Minneapolis, Minnesota, 55455, United States
| | - Medjda Bellamri
- Masonic Cancer Center and Department of Medicinal Chemistry, University of Minnesota, 2231 6 St. SE, Minneapolis, Minnesota, 55455, United States
| | - Robert J. Turesky
- Masonic Cancer Center and Department of Medicinal Chemistry, University of Minnesota, 2231 6 St. SE, Minneapolis, Minnesota, 55455, United States
| |
Collapse
|
6
|
Duan W, Gao L, Kalvala A, Aguila B, Brooks C, Mo X, Ding H, Shilo K, Otterson GA, Villalona-Calero MA. Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice. Int J Cancer 2019; 145:2418-2426. [PMID: 30873587 DOI: 10.1002/ijc.32279] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 01/30/2019] [Accepted: 02/28/2019] [Indexed: 11/11/2022]
Abstract
TP53 and K-ras mutations are two of the major genetic alterations in human nonsmall cell lung cancers. The association between these two genes during lung tumorigenesis is unknown. We evaluated the potential of two common Type I (273H, contact) and Type II (175H, conformational) TP53 mutations to induce lung tumors in transgenic mice, as well as K-ras status, and other driver mutations in these tumors. Among 516 (138 nontransgenic, 207 SPC-TP53-273H, 171 SPC-TP53-175H) mice analyzed, 91 tumors, all adenocarcinomas, were observed. Type II mutants developed tumors more frequently (as compared to nontransgenics, p = 0.0003; and Type I, p = 0.010), and had an earlier tumor onset compared to Type I (p = 0.012). K-ras mutations occurred in 21 of 50 (42%) of murine lung tumors sequenced. For both the nontransgenic and the SPC-TP53-273H transgenics, tumor K-ras codon 12-13 mutations occurred after 13 months with a peak incidence at 16-18 months. However, for the SPC-TP53-175H transgenics, K-ras codon 12-13 mutations were observed as early as 6 months, with a peak incidence between the ages of 10-12 months. Codons 12-13 transversion mutations were the predominant changes in the SPC-TP53-175H transgenics, whereas codon 61 transition mutations were more common in the SPC-TP53-273H transgenics. The observation of accelerated tumor onset, early appearance and high frequency of K-ras codon 12-13 mutations in the Type II TP53-175H mice suggests an enhanced oncogenic function of conformational TP53 mutations, and gains in early genetic instability for tumors containing these mutations compared to contact mutations.
Collapse
Affiliation(s)
- Wenrui Duan
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, USA.,Biomolecular Sciences Institute, the Florida International University, Miami, FL, USA.,Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Li Gao
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, USA.,Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Arjun Kalvala
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Brittany Aguila
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Christopher Brooks
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Xiaokui Mo
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Haiming Ding
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Konstantin Shilo
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Gregory A Otterson
- Comprehensive Cancer Center at the Ohio State University College of Medicine and Public Health, Columbus, OH, USA
| | - Miguel A Villalona-Calero
- Department of Human & Molecular Genetics, Herbert Wertheim College of Medicine, The Florida International University, Miami, FL, USA.,Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
| |
Collapse
|
7
|
Frega S, Dal Maso A, Ferro A, Bonanno L, Conte P, Pasello G. Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? Crit Rev Oncol Hematol 2019; 138:87-103. [PMID: 31092389 DOI: 10.1016/j.critrevonc.2019.03.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 03/14/2019] [Accepted: 03/20/2019] [Indexed: 12/24/2022] Open
Abstract
Lung cancer (LC) is the leading cause of cancer-related death worldwide, despite a decreasing incidence rate in recent years, especially in men. Most risk factors for LC could be linked to an individual's reproductive system and secondary sex characteristics ('sex-related') and/or to some physical, behavioral and personality traits ('gender-related') peculiar to males rather than females or vice versa. An imbalance of these etiologic factors could explain why some LC features may differ between sexes. For this review, an extended literature data collection was performed, using keywords to identify 'sex/gender' and 'LC'. Differences between genders in LC epidemiology, pathological and molecular characteristics, loco-regional and/or systemic treatments outcome and prognosis were systematically analyzed. The possible predictive role of physio-pathological factors in males and females paves the way for a personalized therapeutic approach, emphasizing the need to include gender as a stratification factor in future clinical trials design.
Collapse
Affiliation(s)
- Stefano Frega
- Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - Alessandro Dal Maso
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - Alessandra Ferro
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - Laura Bonanno
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Italy
| | - PierFranco Conte
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - Giulia Pasello
- Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Italy.
| |
Collapse
|
8
|
Yates SA, Murphy MF, Moore SA. The effect of malondialdehyde is modified by simian virus 40 transformation in human lung fibroblast cells. Toxicology 2019; 415:1-9. [PMID: 30658077 DOI: 10.1016/j.tox.2019.01.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Revised: 01/11/2019] [Accepted: 01/14/2019] [Indexed: 11/18/2022]
Abstract
The effects of malondialdehyde (MDA), a product of oxidative stress, on normal lung fibroblast cells (MRC5) and transformed cells (MRC5 SV2) showed differing responses between the two cell lines. MRC5 cells showed lower viability at low MDA concentrations (<250 μM) but had better viability at higher concentrations than the transformed cells. Both cell lines showed an increase in the number of micronuclei, nuclear size and a relocation of p53 to the nucleus with increasing MDA. The expression of p53 was higher in the MRC5 cells at 24 h; 2-8 fold induction vs 1-2.5 fold in the MRC5 SV2 cells, but reduced to almost zero at 48 h in the MRC5 cells. Mutation sequencing of the PCR products of a 689 bp region (residues 4640-5328) of the TP53 gene revealed MRC5 had more mutations than MRC5 SV2 cells (n = 21 and 11 respectively) and that they were predominantly insertions (MRC5 81%, MRC5 SV2 100%). A common mutation was observed in both cell lines; a G insertion at residue 4724 (n = 7) which could prove to be a mutational hotspot. These results indicate that the transformed cells are slower to respond to oxidative stress and/or mutagenic compounds. The mutation spectrum of predominantly frameshift mutations (insertions) suggests that oxidative stress plays a minimal role in smoking related lung cancer, but could be of greater importance to other lung diseases and cancer caused by exposures such as passive smokers, passive vapers and atmospheric pollutants.
Collapse
Affiliation(s)
- S A Yates
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK
| | - M F Murphy
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK
| | - S A Moore
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK.
| |
Collapse
|
9
|
Weng MW, Lee HW, Park SH, Hu Y, Wang HT, Chen LC, Rom WN, Huang WC, Lepor H, Wu XR, Yang CS, Tang MS. Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. Proc Natl Acad Sci U S A 2018; 115:E6152-E6161. [PMID: 29915082 PMCID: PMC6142211 DOI: 10.1073/pnas.1804869115] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Tobacco smoke (TS) contains numerous cancer-causing agents, with polycyclic aromatic hydrocarbons (PAHs) and nitrosamines being most frequently cited as the major TS human cancer agents. Many lines of evidence seriously question this conclusion. To resolve this issue, we determined DNA adducts induced by the three major TS carcinogens: benzo(a)pyrene (BP), 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanoe (NNK), and aldehydes in humans and mice. In mice, TS induces abundant aldehyde-induced γ-hydroxy-propano-deoxyguanosine (γ-OH-PdG) and α-methyl-γ-OH-PdG adducts in the lung and bladder, but not in the heart and liver. TS does not induce the BP- and NNK-DNA adducts in lung, heart, liver, and bladder. TS also reduces DNA repair activity and the abundance of repair proteins, XPC and OGG1/2, in lung tissues. These TS effects were greatly reduced by diet with polyphenols. We found that γ-OH-PdG and α-methyl-γ-OH-PdG are the major adducts formed in tobacco smokers' buccal cells as well as the normal lung tissues of tobacco-smoking lung cancer patients, but not in lung tissues of nonsmokers. However, the levels of BP- and NNK-DNA adducts are the same in lung tissues of smokers and nonsmokers. We found that while BP and NNK can induce BPDE-dG and O6-methyl-dG adducts in human lung and bladder epithelial cells, these inductions can be inhibited by acrolein. Acrolein also can reduce DNA repair activity and repair proteins. We propose a TS carcinogenesis paradigm. Aldehydes are major TS carcinogens exerting dominant effect: Aldehydes induce mutagenic PdG adducts, impair DNA repair functions, and inhibit many procarcinogens in TS from becoming DNA-damaging agents.
Collapse
Affiliation(s)
- Mao-Wen Weng
- Department of Environmental Medicine, New York University School of Medicine, Tuxedo Park, NY 10987
| | - Hyun-Wook Lee
- Department of Environmental Medicine, New York University School of Medicine, Tuxedo Park, NY 10987
| | - Sung-Hyun Park
- Department of Environmental Medicine, New York University School of Medicine, Tuxedo Park, NY 10987
| | - Yu Hu
- Department of Environmental Medicine, New York University School of Medicine, Tuxedo Park, NY 10987
| | - Hsing-Tsui Wang
- Department of Environmental Medicine, New York University School of Medicine, Tuxedo Park, NY 10987
| | - Lung-Chi Chen
- Department of Environmental Medicine, New York University School of Medicine, Tuxedo Park, NY 10987
| | - William N Rom
- Department of Medicine, New York University School of Medicine, New York, NY 10016
| | - William C Huang
- Department of Urology, New York University School of Medicine, New York, NY 10016
| | - Herbert Lepor
- Department of Urology, New York University School of Medicine, New York, NY 10016
| | - Xue-Ru Wu
- Department of Urology, New York University School of Medicine, New York, NY 10016
| | - Chung S Yang
- Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854-0789
| | - Moon-Shong Tang
- Department of Environmental Medicine, New York University School of Medicine, Tuxedo Park, NY 10987;
| |
Collapse
|
10
|
Zarredar H, Ansarin K, Baradaran B, Ahdi Khosroshahi S, Farajnia S. Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology. Cancer Invest 2018; 36:37-58. [DOI: 10.1080/07357907.2017.1416393] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Habib Zarredar
- Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran
- Students Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Khalil Ansarin
- Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran
| | - Behzad Baradaran
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | | | - Safar Farajnia
- Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran
- Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
11
|
Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precis Oncol 2017; 2017:PO.17.00146. [PMID: 29951597 PMCID: PMC6016848 DOI: 10.1200/po.17.00146] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
PURPOSE An association between mutational burden and response to immune checkpoint therapy has been documented in several cancer types. The potential for such a mutational burden threshold to predict response to immune checkpoint therapy was evaluated in several clinical datasets, where mutational burden was measured either by whole-exome sequencing (WXS) or using commercially available sequencing panels. METHODS WXS and RNA-seq data of 33 solid cancer types from TCGA were analyzed to determine whether a robust immune checkpoint activating mutation (iCAM) burden threshold associated with evidence of immune checkpoint activation exists in these cancers that may serve as a biomarker for response to immune checkpoint blockade therapy. RESULTS We find that a robust iCAM threshold, associated with signatures of immune checkpoint activation, exists in 8 of 33 solid cancers: melanoma, lung adenocarcinoma, colon adenocarcinoma, endometrial cancer, stomach adenocarcinoma, cervical cancer, ER+HER2- breast cancer, and bladder-urothelial cancer. Tumors with mutational burden higher than the threshold (iCAM+) also had clear histologic evidence of lymphocytic infiltration. In published datasets of melanoma, lung adenocarcinoma and colon cancer, patients with iCAM+ tumors had significantly better response to immune checkpoint therapy compared to those with iCAM- tumors. ROC analysis using TCGA predictions as gold standard showed that iCAM+ tumors are accurately identifiable using clinical sequencing assays, such as FoundationOne or StrandAdvantage. Using the FoundationOne derived threshold, analysis of 113 melanoma tumors, showed that iCAM+ patients have significantly better response to immune checkpoint therapy. iCAM+ and iCAM- tumors have distinct mutation patterns and different immune microenvironments. CONCLUSION In 8 solid cancers, a mutational burden threshold exists that may predict response to immune checkpoint blockade. This threshold is identifiable using available clinical sequencing assays.
Collapse
Affiliation(s)
- Anshuman Panda
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Anil Betigeri
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Kalyanasundaram Subramanian
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Jeffrey S. Ross
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Dean C. Pavlick
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Siraj Ali
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Paul Markowski
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Ann Silk
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Howard L. Kaufman
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Edmund Lattime
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Janice M. Mehnert
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Ryan Sullivan
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Christine M. Lovly
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Jeffrey Sosman
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Douglas B. Johnson
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Gyan Bhanot
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
| | - Shridar Ganesan
- Anshuman Panda, Ann Silk, Howard L. Kaufman, Edmund Lattime, Janice M. Mehnert, Gyan Bhanot, and Shridar Ganesan, Rutgers Cancer Institute of New Jersey; Paul Markowski, Ann Silk, Howard L. Kaufman, Janice M. Mehnert, and Shridar Ganesan, Rutgers Robert Wood Johnson Medical School, New Brunswick; Anshuman Panda and Gyan Bhanot, Rutgers University, Piscataway, NJ; Anil Betigeri and Kalyanasundaram Subramanian, Strand Life Sciences, Bangalore, India; Jeffrey S. Ross, Dean C. Pavlick, and Siraj Ali, Foundation Medicine, Cambridge; Ryan Sullivan, Massachusetts General Hospital, Boston, MA; Christine M. Lovly and Douglas B. Johnson, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN; and Jeffrey Sosman, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL,Corresponding author: Shridar Ganesan, MD, PhD, 195 Little Albany St, New Brunswick, NJ 08903; e-mail:
| |
Collapse
|
12
|
Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, Buchan JR, Cho WC. Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer. Int J Mol Sci 2017; 18:E367. [PMID: 28208579 PMCID: PMC5343902 DOI: 10.3390/ijms18020367] [Citation(s) in RCA: 242] [Impact Index Per Article: 34.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 01/22/2017] [Accepted: 02/03/2017] [Indexed: 02/07/2023] Open
Abstract
Non-small-cell lung cancer (NSCLC) constitutes 85% of all lung cancers, and is the leading cause of cancer-related death worldwide. The poor prognosis and resistance to both radiation and chemotherapy warrant further investigation into the molecular mechanisms of NSCLC and the development of new, more efficacious therapeutics. The processes of autophagy and apoptosis, which induce degradation of proteins and organelles or cell death upon cellular stress, are crucial in the pathophysiology of NSCLC. The close interplay between autophagy and apoptosis through shared signaling pathways complicates our understanding of how NSCLC pathophysiology is regulated. The apoptotic effect of autophagy is controversial as both inhibitory and stimulatory effects have been reported in NSCLC. In addition, crosstalk of proteins regulating both autophagy and apoptosis exists. Here, we review the recent advances of the relationship between autophagy and apoptosis in NSCLC, aiming to provide few insights into the discovery of novel pathogenic factors and the development of new cancer therapeutics.
Collapse
Affiliation(s)
- Guangbo Liu
- Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.
| | - Fen Pei
- Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.
| | - Fengqing Yang
- Department of Obstetrics and Gynecology, Dong'e No. 4 People's Hospital, Liaocheng 252200, China.
| | - Lingxiao Li
- Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
| | - Amit Dipak Amin
- Department of Medicine, Division of Hematology-Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
| | - Songnian Liu
- Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23284, USA.
| | - J Ross Buchan
- Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.
| | - William C Cho
- Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.
| |
Collapse
|
13
|
Yamada Y, Iwata KI, Blyth BJ, Doi K, Morioka T, Daino K, Nishimura M, Kakinuma S, Shimada Y. Effect of Age at Exposure on the Incidence of Lung and Mammary Cancer after Thoracic X-Ray Irradiation in Wistar Rats. Radiat Res 2017; 187:210-220. [DOI: 10.1667/rr14478.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
| | | | | | - Kazutaka Doi
- Fukushima Project Headquarters, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | | | | | | | | | | |
Collapse
|
14
|
|
15
|
The environmental carcinogen benzo[a]pyrene induces a Warburg-like metabolic reprogramming dependent on NHE1 and associated with cell survival. Sci Rep 2016; 6:30776. [PMID: 27488617 PMCID: PMC4973274 DOI: 10.1038/srep30776] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 07/10/2016] [Indexed: 12/30/2022] Open
Abstract
Cancer cells display alterations in many cellular processes. One core hallmark of cancer is the Warburg effect which is a glycolytic reprogramming that allows cells to survive and proliferate. Although the contributions of environmental contaminants to cancer development are widely accepted, the underlying mechanisms have to be clarified. Benzo[a]pyrene (B[a]P), the prototype of polycyclic aromatic hydrocarbons, exhibits genotoxic and carcinogenic effects, and it is a human carcinogen according to the International Agency for Research on Cancer. In addition to triggering apoptotic signals, B[a]P may induce survival signals, both of which are likely to be involved in cancer promotion. We previously suggested that B[a]P-induced mitochondrial dysfunctions, especially membrane hyperpolarization, might trigger cell survival signaling in rat hepatic epithelial F258 cells. Here, we further characterized these dysfunctions by focusing on energy metabolism. We found that B[a]P promoted a metabolic reprogramming. Cell respiration decreased and lactate production increased. These changes were associated with alterations in the tricarboxylic acid cycle which likely involve a dysfunction of the mitochondrial complex II. The glycolytic shift relied on activation of the Na+/H+ exchanger 1 (NHE1) and appeared to be a key feature in B[a]P-induced cell survival related to changes in cell phenotype (epithelial-to-mesenchymal transition and cell migration).
Collapse
|
16
|
Hong HHL, Hoenerhoff MJ, Ton TV, Herbert RA, Kissling GE, Hooth MJ, Behl M, Witt KL, Smith-Roe SL, Sills RC, Pandiri AR. Kras, Egfr, and Tp53 Mutations in B6C3F1/N Mouse and F344/NTac Rat Alveolar/Bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt Metal. Toxicol Pathol 2015; 43:872-82. [PMID: 26059825 DOI: 10.1177/0192623315581192] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Rodent lung tumors are morphologically similar to a subtype of human lung adenocarcinomas. The objective of this study was to evaluate Kirsten rat sarcoma oncogene homolog (Kras), epidermal growth factor receptor (Egfr), and tumor protein 53 (Tp53) mutations, which are relevant to human lung cancer, in cobalt metal dust (CMD)-induced alveolar/bronchiolar tumors of B6C3F1/N mice and F344/NTac rats. Kras mutations were detected in 67% (mice) and 31% (rats) of CMD-induced lung tumors and were predominantly exon 1 codon 12 G to T transversions (80% in mice and 57% in rats). Egfr mutations were detected in 17% (both mice and rats) of CMD-induced lung tumors and were predominantly in exon 20 with 50% G to A transitions (mice and rats). Tp53 mutations were detected in 19% (mice) and 23% (rats) of CMD-induced lung tumors and were predominant in exon 5 (mice, 69% transversions) and exon 6 (rats, all transitions). No mutations were observed for these genes in spontaneous lung tumors or normal lungs from untreated controls. Ames assay indicated that CMD is mutagenic in the absence but not in the presence of S9 mix. Thus, the mutation data (G to T transversions) and Ames assay results suggest that oxidative damage to DNA may be a contributing factor in CMD-induced pulmonary carcinogenesis in rodents.
Collapse
Affiliation(s)
- Hue-Hua L Hong
- Cellular and Molecular Pathology Branch, Division of the National Toxicology Program (NTP), National Institute of Environmental Health Science (NIEHS), Research Triangle Park, North Carolina, USA
| | - Mark J Hoenerhoff
- Cellular and Molecular Pathology Branch, Division of the National Toxicology Program (NTP), National Institute of Environmental Health Science (NIEHS), Research Triangle Park, North Carolina, USA Current address: University of Michigan, Ann Arbor, Michigan, USA
| | - Thai-Vu Ton
- Cellular and Molecular Pathology Branch, Division of the National Toxicology Program (NTP), National Institute of Environmental Health Science (NIEHS), Research Triangle Park, North Carolina, USA
| | - Ronald A Herbert
- Cellular and Molecular Pathology Branch, Division of the National Toxicology Program (NTP), National Institute of Environmental Health Science (NIEHS), Research Triangle Park, North Carolina, USA
| | - Grace E Kissling
- Biostatistics Branch, NTP, NIEHS, Research Triangle Park, North Carolina, USA
| | - Michelle J Hooth
- Program Operations Branch, DNTP, NIEHS, Research Triangle Park, North Carolina, USA
| | - Mamta Behl
- Toxicology Branch, NTP, NIEHS, Research Triangle Park, North Carolina, USA
| | - Kristine L Witt
- Biomolecular Screening Branch, NTP, NIEHS, Research Triangle Park, North Carolina, USA
| | - Stephanie L Smith-Roe
- Biomolecular Screening Branch, NTP, NIEHS, Research Triangle Park, North Carolina, USA
| | - Robert C Sills
- Cellular and Molecular Pathology Branch, Division of the National Toxicology Program (NTP), National Institute of Environmental Health Science (NIEHS), Research Triangle Park, North Carolina, USA
| | - Arun R Pandiri
- Cellular and Molecular Pathology Branch, Division of the National Toxicology Program (NTP), National Institute of Environmental Health Science (NIEHS), Research Triangle Park, North Carolina, USA Experimental Pathology Laboratories, Inc., Durham, North Carolina, USA
| |
Collapse
|
17
|
Ceccaroli C, Pulliero A, Geretto M, Izzotti A. Molecular fingerprints of environmental carcinogens in human cancer. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH. PART C, ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS 2015; 33:188-228. [PMID: 26023758 DOI: 10.1080/10590501.2015.1030491] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Identification of specific molecular changes (fingerprints) is important to identify cancer etiology. Exploitable biomarkers are related to DNA, epigenetics, and proteins. DNA adducts are the turning point between environmental exposures and biological damage. DNA mutational fingerprints are induced by carcinogens in tumor suppressor and oncogenes. In an epigenetic domain, methylation changes occurs in specific genes for arsenic, benzene, chromium, and cigarette smoke. Alteration of specific microRNA has been reported for environmental carcinogens. Benzo(a)pyrene, cadmium, coal, and wood dust hits specific heat-shock proteins and metalloproteases. The multiple analysis of these biomarkers provides information on the carcinogenic mechanisms activated by exposure to environmental carcinogens.
Collapse
Affiliation(s)
- C Ceccaroli
- a Department of Health Sciences, University of Genoa , Italy
| | | | | | | |
Collapse
|
18
|
Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia. Hum Mutat 2014; 35:663-71. [DOI: 10.1002/humu.22508] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 01/03/2014] [Indexed: 01/22/2023]
Affiliation(s)
- Jitka Malcikova
- Central European Institute of Technology; Center of Molecular Medicine, and Faculty of Medicine; Department of Internal Medicine - Hematology and Oncology; Masaryk University; Brno Czech Republic
| | - Sarka Pavlova
- Central European Institute of Technology; Center of Molecular Medicine, and Faculty of Medicine; Department of Internal Medicine - Hematology and Oncology; Masaryk University; Brno Czech Republic
| | - Katerina Stano Kozubik
- Central European Institute of Technology; Center of Molecular Medicine, and Faculty of Medicine; Department of Internal Medicine - Hematology and Oncology; Masaryk University; Brno Czech Republic
| | - Sarka Pospisilova
- Central European Institute of Technology; Center of Molecular Medicine, and Faculty of Medicine; Department of Internal Medicine - Hematology and Oncology; Masaryk University; Brno Czech Republic
| |
Collapse
|
19
|
TP53 aberrations in chronic lymphocytic leukemia. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2013; 792:109-31. [PMID: 24014294 DOI: 10.1007/978-1-4614-8051-8_5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
CLL patients harboring TP53 defects remain the most challenging group in terms of designing rational and effective therapy. Irrespective of the treatment employed-chemotherapy, chemoimmunotherapy, or pure biological drugs-median survival of these patients does not exceed 3-4 years. This adverse outcome is caused by a less effective response to therapeutics acting through DNA damage induction and relying on the subsequent initiation of apoptosis as well as by virtually inevitable aggressive relapse. Patient proportions with TP53 defects at diagnosis or before first therapy were reported within the range 5-15 %, but they increase dramatically in pretreated cohorts (reported up to 44 %), and also in patients with Richter transformation (50 % harbor TP53 defects). Currently, most laboratories monitor TP53 defect as presence of 17p deletion using I-FISH, but 23-45 % of TP53-affected patients were shown to harbor only mutation(s). In other patients with intact TP53, the p53 pathway may be impaired by mutations in ATM gene coding for the p53-regulatory kinase; however, prognosis of ATM-defective patients is not as poor as those with TP53 abnormalities. Though many novel agents are under development, the monoclonal antibody alemtuzumab and allogeneic stem cell transplantation remain the basic treatment options for TP53-affected CLL patients.
Collapse
|
20
|
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers--a review. Eur J Cancer 2012; 48:1299-311. [PMID: 22464348 DOI: 10.1016/j.ejca.2012.03.007] [Citation(s) in RCA: 306] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2012] [Accepted: 03/06/2012] [Indexed: 12/25/2022]
Abstract
An estimated 10-25% of lung cancers worldwide occur in never smokers, i.e. individuals having smoked less than 100 cigarettes in their lifetime. Lung cancer in never smokers (LCINS) is more frequent in women, although large geographic variations are found. Histologically, adenocarcinomas predominate. The mere existence of LCINS suggests that risk factors other than smoking must be present. Exposure to environmental tobacco smoke (particularly in women) and exposure to workplace carcinogens (particularly in men) are the two most important alternative risk factors. However, a history of either is absent in more than a third of LCINS. The large proportion of women in LCINS suggest a hormonal element that may interact with other identified factors such as hereditary risks, a history of respiratory infections or disease, exposure to air pollution, cooking and heating fumes, or exposure to ionising radiation. The study of genomic polymorphisms finds constitutive DNA variations across subjects according to their smoking status, particularly in genes coding for enzymes that participate in the metabolism of certain carcinogens, in those coding for DNA repair enzymes, or in genes associated with tobacco addiction, or inflammatory processes. The type of molecular mutation in p53 or KRAS varies with smoking status. EGFR mutations are more frequent in never smokers, as are EML4-ALK fusions. The mutually exclusive nature of certain mutations is a strong argument in favour of separate genetic paths to cancer for ever smokers and never smokers. In the present paper we review current clinical and molecular aspects of LCINS.
Collapse
Affiliation(s)
- Sébastien Couraud
- Service de Pneumologie et Oncologie Thoracique, Hospices Civils de Lyon, CH Lyon Sud, et Université Lyon 1, Lyon, France.
| | | | | | | | | |
Collapse
|
21
|
Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice. Mol Cell Biol 2011; 31:3832-44. [PMID: 21791616 DOI: 10.1128/mcb.05744-11] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Strong evidence has indicated that protein phosphatase 2A (PP2A) is a tumor suppressor, but a mouse model for testing the tumor suppressor activity was missing. The most abundant forms of trimeric PP2A holoenzyme consist of the scaffolding Aα subunit, one of several regulatory B subunits, and the catalytic Cα subunit. Aα mutations were discovered in a variety of human carcinomas. All carcinoma-associated mutant Aα subunits are defective in binding the B or B and C subunits. Here we describe two knock-in mice expressing cancer-associated Aα point mutants defective in binding B' subunits, one knockout mouse expressing truncated Aα defective in B and C subunit binding, and a floxed mouse for generating conditional Aα knockouts. We found that the cancer-associated Aα mutations increased the incidence of cancer by 50 to 60% in lungs of FVB mice treated with benzopyrene, demonstrating that PP2A acts as a tumor suppressor. We show that the effect of Aα mutation on cancer incidence is dependent on the tumor suppressor p53. The finding that the Aα mutation E64D, which was detected in a human lung carcinoma, increases the lung cancer incidence in mice suggests that this mutation also played a role in the development of the carcinoma in which it was discovered.
Collapse
|
22
|
Wen J, Fu J, Zhang W, Guo M. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod Pathol 2011; 24:932-43. [PMID: 21423157 DOI: 10.1038/modpathol.2011.46] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Lung cancer is the leading cause of cancer deaths worldwide. Recent advance in targeted therapy for lung cancer patients with epidermal growth factor receptor (EGFR) mutations has demonstrated a promising development toward personalized therapy for lung cancer patients. The development of lung cancer is a complex process, involving a series of genetic and epigenetic changes. Tobacco smoke is the predominant etiologic risk factor for lung cancer. However, some lung cancers, especially adenocarcinomas, arise in patients who have never smoked, suggesting the importance of host genetic/epigenetic susceptibility in the occurrence and development of lung cancer. Understanding of these genetic and epigenetic changes will further aid in the biomarker-driven personalized therapy for lung cancer patients. In this review, we summarize the genetic and epigenetic alterations observed in lung cancers, including chromosomal loss of heterozygosity, tumor-suppressor gene mutation, gene methylation, histone modification, and microRNA expression changes. Clinical and preclinical studies have implied specific genetic/epigenetic changes for clinical application in lung cancer patients. However, more efforts are required in validation of the identified molecular markers in lung cancer patients for early detections, assessment for treatment response, and survival predictions.
Collapse
Affiliation(s)
- Jing Wen
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | | | | | | |
Collapse
|
23
|
TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011; 2011:583929. [PMID: 21331359 PMCID: PMC3035360 DOI: 10.1155/2011/583929] [Citation(s) in RCA: 217] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 11/28/2010] [Accepted: 12/20/2010] [Indexed: 11/17/2022] Open
Abstract
The tumor suppressor gene TP53 is frequently mutated in human cancers. Abnormality of the TP53 gene is one of the most significant events in lung cancers and plays an important role in the tumorigenesis of lung epithelial cells. Human lung cancers are classified into two major types, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). The latter accounts for approximately 80% of all primary lung cancers, and the incidence of NSCLC is increasing yearly. Most clinical studies suggest that NSCLC with TP53 alterations carries a worse prognosis and may be relatively more resistant to chemotherapy and radiation. A deep understanding of the role of TP53 in lung carcinogenesis may lead to a more reasonably targeted clinical approach, which should be exploited to enhance the survival rates of patients with lung cancer. This paper will focus on the role of TP53 in the molecular pathogenesis, epidemiology, and therapeutic strategies of TP53 mutation in NSCLC.
Collapse
|
24
|
Hang B. Formation and repair of tobacco carcinogen-derived bulky DNA adducts. J Nucleic Acids 2010; 2010:709521. [PMID: 21234336 PMCID: PMC3017938 DOI: 10.4061/2010/709521] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2010] [Revised: 07/16/2010] [Accepted: 09/17/2010] [Indexed: 01/08/2023] Open
Abstract
DNA adducts play a central role in chemical carcinogenesis. The analysis of formation and repair of smoking-related DNA adducts remains particularly challenging as both smokers and nonsmokers exposed to smoke are repetitively under attack from complex mixtures of carcinogens such as polycyclic aromatic hydrocarbons and N-nitrosamines. The bulky DNA adducts, which usually have complex structure, are particularly important because of their biological relevance. Several known cellular DNA repair pathways have been known to operate in human cells on specific types of bulky DNA adducts, for example, nucleotide excision repair, base excision repair, and direct reversal involving O6-alkylguanine DNA alkyltransferase or AlkB homologs. Understanding the mechanisms of adduct formation and repair processes is critical for the assessment of cancer risk resulting from exposure to cigarette smoke, and ultimately for developing strategies of cancer prevention. This paper highlights the recent progress made in the areas concerning formation and repair of bulky DNA adducts in the context of tobacco carcinogen-associated genotoxic and carcinogenic effects.
Collapse
Affiliation(s)
- Bo Hang
- Life Sciences Division, Department of Cancer and DNA Damage Responses, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| |
Collapse
|
25
|
Stojsic J, Stevic R, Kontic M, Stojsic Z, Drndarevic N, Bunjevacki V, Jekic B. Large cell lung carcinoma with unusual imaging feature, immunophenotype and genetic finding. Pathol Oncol Res 2010; 17:175-9. [PMID: 20405348 DOI: 10.1007/s12253-010-9272-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Accepted: 04/06/2010] [Indexed: 11/30/2022]
Abstract
We present a case of large cell lung carcinoma in sixty-one year old male with typical lung cancer symptoms but unusual radiological presentation and immunophenotype. Tumor morphological finding related to its radiological finding was suggestive for large cell lymphoma or carcinoma, but its immunophenotype made confusion for pathological diagnosis. No p53 mutations were detected in genetic investigation. Multidisciplinary diagnostic approach to some tumors is useful for their final diagnosis.
Collapse
Affiliation(s)
- Jelena Stojsic
- Institute for Lung Diseases and Tuberculosis, Clinical Centre of Serbia, Belgrade, Serbia.
| | | | | | | | | | | | | |
Collapse
|
26
|
Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2010; 15:5646-61. [PMID: 19755392 DOI: 10.1158/1078-0432.ccr-09-0377] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The majority of lung cancers are caused by long term exposure to the several classes of carcinogens present in tobacco smoke. Although a significant fraction of lung cancers in never smokers may also be attributable to tobacco, many such cancers arise in the absence of detectable tobacco exposure, and may follow a very different cellular and molecular pathway of malignant transformation. Recent studies summarized here suggest that lung cancers arising in never smokers have a distinct natural history, profile of oncogenic mutations, and response to targeted therapy. The majority of molecular analyses of lung cancer have focused on genetic profiling of pathways responsible for metabolism of primary tobacco carcinogens. Limited research has been conducted evaluating familial aggregation and genetic linkage of lung cancer, particularly among never smokers in whom such associations might be expected to be strongest. Data emerging over the past several years show that lung cancers in never smokers are much more likely to carry activating mutations of the epidermal growth factor receptor (EGFR), a key oncogenic factor and direct therapeutic target of several newer anticancer drugs. EGFR mutant lung cancers may represent a distinct class of lung cancers, enriched in the never-smoking population, and less clearly linked to direct tobacco carcinogenesis. These insights followed initial testing and demonstration of efficacy of EGFR-targeted drugs. Focused analysis of molecular carcinogenesis in lung cancers in never smokers is needed, and may provide additional biologic insight with therapeutic implications for lung cancers in both ever smokers and never smokers.
Collapse
Affiliation(s)
- Charles M Rudin
- Johns Hopkins University School of Medicine, David H. Koch Cancer Research Building, Room 544, 1550 Orleans Street, Baltimore, MD 21231, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Ruano-Ravina A, Faraldo-Vallés MJ, Barros-Dios JM. Is there a specific mutation of p53 gene due to radon exposure? A systematic review. Int J Radiat Biol 2009; 85:614-21. [DOI: 10.1080/09553000902954504] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
28
|
Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, Barsky SH, Otterson GA, Villalona-Calero MA. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS One 2009; 4:e5563. [PMID: 19440353 PMCID: PMC2680060 DOI: 10.1371/journal.pone.0005563] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2009] [Accepted: 04/18/2009] [Indexed: 11/30/2022] Open
Abstract
Background Mutations in the P53 gene are among the most common genetic abnormalities in human lung cancer. Codon 273 in the sequence-specific DNA binding domain is one of the most frequently mutated sites. Methodology To investigate the role of mutant p53 in lung tumorigenesis, a lung specific p53(273H) transgenic mouse model was developed. Rates of lung cancer formation in the transgenic animals and their littermates were evaluated by necropsy studies performed in progressive age cohorts ranging from 4 to 24 months. In order to establish the influence of other common genetic abnormalities in lung tumor formation in the animals, K-Ras gene mutation and p16INK4a (p16) promoter methylation were evaluated in a total of 281 transgenic mice and 189 non-transgenic littermates. Principal Findings At the age extremes of 4–12 and 22–24 months no differences were observed, with very low prevalence of tumors in animals younger than 12 months, and a relatively high prevalence at age 22 months or older. However, the transgenic mice had a significant higher lung tumor rate than their non-transgenic counterparts during the age of 13–21 months, suggesting an age-related shift in lung tumor formation induced by the lung-specific expression of the human mutant p53. Histopathology suggested a more aggressive nature for the transgenic tumors. Older mice (>13 months) had a significantly higher rate of p16 promoter methylation (17% v 82%). In addition, an age related effect was observed for K-Ras codons 12 or 13 mutations, but not for codon 61 mutations. Conclusions/Significance These results would suggest that the mutant p53(273H) contributes to an acceleration in the development of spontaneous lung tumors in these mice. Combination with other genetic and epigenetic alterations occurring after the age of 13 months is intimately linked to its oncogenic potential.
Collapse
Affiliation(s)
- Wenrui Duan
- Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, United States of America
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Gao W, Mady HH, Melhem MF, Keohavong P. Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients. Mol Carcinog 2008; 48:633-41. [DOI: 10.1002/mc.20505] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
30
|
Spencer PJ, Yano BL, Gollapudi BB. The Tg.AC Transgenic Mouse as a Screening Tool for Anticarcinogens: Broccoli Juice Protected Against 12-O-Tetradecanoylphorbol-13-Acetate (TPA) But Not Benzo[a]Pyrene (B[a]P)-Induced Skin Tumors. Toxicol Mech Methods 2008; 16:189-98. [DOI: 10.1080/15376520600620141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
31
|
Sudo H, Li-Sucholeiki XC, Marcelino LA, Gruhl AN, Herrero-Jimenez P, Zarbl H, Willey JC, Furth EE, Morgenthaler S, Coller HA, Ekstrom PO, Kurzweil R, Gostjeva EV, Thilly WG. Fetal-juvenile origins of point mutations in the adult human tracheal-bronchial epithelium: absence of detectable effects of age, gender or smoking status. Mutat Res 2008; 646:25-40. [PMID: 18824180 DOI: 10.1016/j.mrfmmm.2008.08.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2007] [Revised: 08/21/2008] [Accepted: 08/29/2008] [Indexed: 11/19/2022]
Abstract
Allele-specific mismatch amplification mutation assays (MAMA) of anatomically distinct sectors of the upper bronchial tracts of nine nonsmokers revealed many numerically dispersed clusters of the point mutations C742T, G746T, G747T of the TP53 gene, G35T of the KRAS gene and G508A of the HPRT1 gene. Assays of these five mutations in six smokers have yielded quantitatively similar results. One hundred and eighty four micro-anatomical sectors of 0.5-6x10(6) tracheal-bronchial epithelial cells represented en toto the equivalent of approximately 1.7 human smokers' bronchial trees to the fifth bifurcation. Statistically significant mutant copy numbers above the 95% upper confidence limits of historical background controls were found in 198 of 425 sector assays. No significant differences (P=0.1) for negative sector fractions, mutant fractions, distributions of mutant cluster size or anatomical positions were observed for smoking status, gender or age (38-76 year). Based on the modal cluster size of mitochondrial point mutants, the size of the adult bronchial epithelial maintenance turnover unit was estimated to be about 32 cells. When data from all 15 lungs were combined the log2 of nuclear mutant cluster size plotted against log2 of the number of clusters of a given cluster size displayed a slope of approximately 1.1 over a range of cluster sizes from approximately 2(6) to 2(15) mutant copies. A parsimonious interpretation of these nuclear and previously reported data for lung epithelial mitochondrial point mutant clusters is that they arose from mutations in stem cells at a high but constant rate per stem cell doubling during at least ten stem cell doublings of the later fetal-juvenile period. The upper and lower decile range of summed point mutant fractions among lungs was about 7.5-fold, suggesting an important source of stratification in the population with regard to risk of tumor initiation.
Collapse
Affiliation(s)
- Hiroko Sudo
- Massachusetts Institute of Technology, Department of Biological Engineering, 21 Ames St., 16-743 Cambridge, MA 02139, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Reid ME, Santella R, Ambrosone CB. Molecular epidemiology to better predict lung cancer risk. Clin Lung Cancer 2008; 9:149-53. [PMID: 18621624 DOI: 10.3816/clc.2008.n.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Although it is clear that smoking causes lung cancer, it is not known why some smokers develop the disease while others do not. Little is also known regarding risk factors for lung cancer among never-smokers, particularly women, or why women with lung cancer are more likely to have a family history of cancer, to be diagnosed at a young age, or to have adenocarcinoma. The application of molecular epidemiology to the study of lung cancer risk might facilitate elucidation of these questions. In this review, the molecular epidemiology of lung cancer is discussed, with an emphasis on studies of genetic variability in metabolic pathways as a means for determining susceptibility. Work that has assessed intermediate markers of risk, such as DNA adducts, is also presented, as are studies of tumor tissue alterations, such as mutations and DNA methylation, in relation to risk of lung cancer. Finally, approaches to evaluating factors that might explain the differing epidemiology of lung cancer between men and women are also presented. It is likely that, by incorporating biomarkers of susceptibility, exposure, and effect, molecular epidemiologic approaches might better define factors that explain some of the variability in lung cancer risk.
Collapse
Affiliation(s)
- Mary E Reid
- Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | |
Collapse
|
33
|
Abstract
Lung cancer is a major cause of cancer-related mortality in the USA, and tobacco smoke is the major risk factor for this disease. However, many patients with lung cancer have never smoked (never smokers). Patients with lung cancer who have never smoked are more likely to have mutations in epidermal growth factor receptor (EGFR) tyrosine kinase and have better response to its inhibitors than do patients with tobacco-associated lung cancer. Furthermore, the prevalences of mutations in KRAS and P53 differ for patients with lung cancer who have never smoked and those with tobacco-associated lung cancer. Genetic mutations seem to be more common in patients with tobacco-associated lung cancer than in never smokers. Current evidence indicates that the two types of lung cancer are biologically distinct. Here, we review published studies of the molecular genetics of lung cancer in never smokers and identify the specific differences from tobacco-associated lung cancer.
Collapse
|
34
|
Paget V, Lechevrel M, Sichel F. Acetaldehyde-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a functional assay, the FASAY (functional analysis of separated alleles in yeast). MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2008; 652:12-9. [DOI: 10.1016/j.mrgentox.2007.11.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2007] [Revised: 10/22/2007] [Accepted: 11/21/2007] [Indexed: 10/22/2022]
|
35
|
Hagiwara N, Mechanic LE, Trivers GE, Cawley HL, Taga M, Bowman ED, Kumamoto K, He P, Bernard M, Doja S, Miyashita M, Tajiri T, Sasajima K, Nomura T, Makino H, Takahashi K, Hussain SP, Harris CC. Quantitative detection of p53 mutations in plasma DNA from tobacco smokers. Cancer Res 2007; 66:8309-17. [PMID: 16912213 DOI: 10.1158/0008-5472.can-06-0991] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In lung tumors, the p53 tumor suppressor gene is commonly mutated with a characteristic mutation spectrum. The amount of and alterations in plasma DNA, such as mutations in p53, were associated with several cancers. Few studies used quantitative methods of high sensitivity. Previously, we observed p53 mutations in the noncancerous tissue that differed from those in lung tumors using the highly sensitive p53 mutation load assay. Based on our observation of an increased p53 mutation load in nontumorous lung tissue in smokers, we hypothesized that plasma DNA may contain mutant p53 indicative of tobacco smoke exposure and will be an effective biomarker of lung cancer or smoking exposure. We modified the p53 mutation load assay to detect mutations at p53 codons 248 and 249, common mutations in lung cancer, in plasma DNA samples with a sensitivity of 1:5,000. The assay was applied to a set of lung cancer cases (n = 39), hospital controls (n = 21), and population controls (n = 20) from a larger study. Controls were selected to consist of equal numbers of both ever and never smokers. The p53 mutation load (mutated p53 copies per total number of p53 copies) was associated with smoking (P = 0.06), but not with lung cancer (P = 0.59). Most of the individuals with p53 mutations observed in plasma DNA were ever smokers and the p53 mutation load was higher in those who smoked for longer durations (P = 0.04). In summary, we were able to detect p53 mutations in plasma DNA from healthy individuals and our data suggest that p53 mutations in plasma DNA may be a marker of carcinogen exposure from tobacco smoke.
Collapse
Affiliation(s)
- Nobutoshi Hagiwara
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4258, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Ruano-Ravina A, Pérez-Becerra R, Fraga M, Kelsey KT, Barros-Dios JM. Analysis of the relationship between p53 immunohistochemical expression and risk factors for lung cancer, with special emphasis on residential radon exposure. Ann Oncol 2007; 19:109-14. [PMID: 17897960 DOI: 10.1093/annonc/mdm395] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Indoor radon exposure has been postulated as the second risk factor of lung cancer after tobacco. The objective of this work is to analyze if there exists any effect on p53 immunohistochemical expression mainly due to radon exposure and other risk factors for lung cancer. PATIENTS AND METHODS The tumor samples of a case series of 163 lung cancer cases were analyzed to know the p53 staining. The staining was classified into four categories from no staining to intense staining (>60%). This staining was correlated with radon exposure, tobacco consumption, having worked in risk occupations for lung cancer and alcohol consumption. RESULTS Only 72 samples could be analyzed for immunohistochemistry and some of these samples were sequenced from exons 4-8. No association was observed for staining intensity and radon exposure and also for tobacco and occupation. A slight association with a more intense staining was observed for high alcohol intake. In the four samples with a staining >60% that could be sequenced from exons 4 to 8, no mutation was observed in the p53 gene. CONCLUSION There is no association between radon exposure and p53 expression, indicating that maybe the effect of radon is not mediated through p53 alterations.
Collapse
MESH Headings
- Aged
- Air Pollutants, Radioactive/adverse effects
- Air Pollution, Indoor/adverse effects
- Alcohol Drinking/adverse effects
- Biomarkers, Tumor/analysis
- Carcinoma, Non-Small-Cell Lung/chemistry
- Carcinoma, Non-Small-Cell Lung/epidemiology
- Carcinoma, Non-Small-Cell Lung/etiology
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Small Cell/chemistry
- Carcinoma, Small Cell/epidemiology
- Carcinoma, Small Cell/etiology
- Carcinoma, Small Cell/pathology
- Case-Control Studies
- Cocarcinogenesis
- Female
- Humans
- Lung Neoplasms/chemistry
- Lung Neoplasms/epidemiology
- Lung Neoplasms/etiology
- Lung Neoplasms/pathology
- Male
- Middle Aged
- Neoplasms, Radiation-Induced/chemistry
- Neoplasms, Radiation-Induced/etiology
- Occupational Exposure
- Radon/adverse effects
- Residence Characteristics
- Risk Factors
- Smoking/adverse effects
- Spain/epidemiology
- Tumor Suppressor Protein p53/analysis
- Tumor Suppressor Protein p53/physiology
Collapse
Affiliation(s)
- A Ruano-Ravina
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
| | | | | | | | | |
Collapse
|
37
|
Yoshino I, Kometani T, Shoji F, Osoegawa A, Ohba T, Kouso H, Takenaka T, Yohena T, Maehara Y. Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer 2007; 110:369-74. [PMID: 17559143 DOI: 10.1002/cncr.22728] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND It is believed that epithelial-mesenchymal transition (EMT) occurs during the development and progression of cancer; however, the correlation between tobacco smoking and EMT remains to be elucidated. METHODS Cells from the bronchioloalveolar carcinoma cell line A549 were exposed to benzo(a)pyrene (B[a]P) for 24 weeks, and morphology, proliferative activity, and gene expression profiles were analyzed. RESULTS Although no apparent morphologic changes were observed, the B[a]P-exposed A549 cells exhibited enhanced proliferative activity in 1% bovine serum that contained medium, and dramatic changes in expression levels were observed in a large number of genes. Of those, the expression of EMT-related genes, such as migration-stimulating factor, plasminogen activator inhibitor-1, fibronectin, twist, transforming growth factor-beta2, basic fibroblast growth factor, and electron transport system, were up-regulated; whereas gene expression of E-cadherin was decreased. Most enhanced expression levels remained 8 weeks after the retrieval of B[a]P in culture. CONCLUSIONS The current results indicated that B[a]P seems to induce EMT in lung cancer cells, and it also may drive disease progression in patients with lung cancer.
Collapse
Affiliation(s)
- Ichiro Yoshino
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis 2007; 28:1851-8. [PMID: 17693665 PMCID: PMC2131731 DOI: 10.1093/carcin/bgm176] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Cancer is a complex disease that involves the accumulation of both genetic and epigenetic alterations of numerous genes. Data in the Genetic Alterations in Cancer database for gene mutations and allelic loss [loss of heterozygosity (LOH)] in human tumors (e.g. lung, oral, esophagus, stomach and colon/rectum) were reviewed. Results for the genes and pathways implicated in tumor development at these sites are presented. Mutation incidence, spectra and codon specificity are described for lung, larynx and oral tumors. LOH occurred more frequently than gene mutations in tumors from all sites examined. The cell cycle gene, TP53 (all sites), and cell signaling gene, APC (colorectal and gastric cancers), were the only genes with similar incidences of LOH and mutation. Alterations of one or more cell cycle and cell signaling genes were reported for tumors from each site. Site-specific activation was apparent in the cell signaling mitogen-activated protein kinase oncogenes (KRAS in lung, HRAS in oral cancers and BRAF in esophageal and colorectal cancers). Analysis of genetic changes in lung tumors showed that the incidence of mutations in the TP53 and KRAS genes and the incidence of LOH in the FHIT gene were significantly greater in smokers versus non-smokers (P < 0.01). In lung and oral cancers, the TP53 GC --> TA transversion frequency increased with tobacco smoke exposure (P < 0.05). Furthermore, the TP53 mutational hot spots for lung and laryngeal cancers from smokers included codons 157, 245 and 273, whereas for oral tumors included codons 280 and 281.
Collapse
Affiliation(s)
- I A Lea
- Integrated Laboratory Systems, Inc., Research Triangle Park, NC 27709, USA.
| | | | | | | | | | | |
Collapse
|
39
|
Peltonen J, Welsh JA, Vähäkangas KH. Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? Hum Exp Toxicol 2007; 26:9-18. [PMID: 17334176 DOI: 10.1177/0960327107071918] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Mutation analysis methods have increased in variety during the past years. High-throughput microarray methods have especially increased in popularity. However, new methods require reference points, and not all of the methods are equal in sensitivity and specificity. Furthermore, the detection of unknown missense mutations, such as unknown TP53 mutations in human tumors, for clinical purposes requires great accuracy, which may be difficult to acquire with the current high-throughput methods. For these reasons, the classical methods, such as PCR-manual sequencing and PCR-SSCP, are still valuable and necessary.
Collapse
Affiliation(s)
- J Peltonen
- Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | | | | |
Collapse
|
40
|
Yim HW, Slebos RJC, Randell SH, Umbach DM, Parsons AM, Rivera MP, Detterbeck FC, Taylor JA. Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. Cancer Lett 2007; 246:24-33. [PMID: 16517060 DOI: 10.1016/j.canlet.2006.01.023] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2005] [Revised: 01/17/2006] [Accepted: 01/24/2006] [Indexed: 11/23/2022]
Abstract
Telomerase plays an important role in the maintenance of telomere ends in normal and tumor cells and ectopic expression can immortalize human bronchial epithelial (HBE) cells. We assessed telomerase activation, growth properties and methylation status in the hTERT promoter in a panel of HBE cell cultures in relation to smoking and previous lung cancer history. HBE cells were obtained from a total of 26 subjects, six of whom were lifelong non-smokers, while 20 subjects had a smoking history, including seven who had lung carcinoma. Telomerase activity was determined using the telomeric repeat amplification protocol (TRAP). Maximum passage number and time to senescence were also determined through extended culturing. The distribution of the telomerase activity between ever-smokers and never-smokers was significantly different (P=0.03, F-test), and there was a strong correlation between telomerase activity and the number of pack-years smoked (P=0.0012, F-test for slope). A small difference in telomerase activity was observed according to lung cancer status (P=0.02, F-test). Telomerase activity was not correlated with maximum passage number after extended culturing or with time to senescence. None of the HBE cultures demonstrated methylation of the hTERT promoter. Our results indicate an association between tobacco carcinogen exposure and telomerase activity in normal bronchial epithelium, although a causative role of tobacco smoking in the (re)activation of telomerase can not be proven. An increase in telomerase activity in normal bronchial epithelium might extend the lifespan of cells at risk for malignant transformation, and thus contribute to lung carcinogenesis.
Collapse
Affiliation(s)
- Hyeon Woo Yim
- Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Warnakulasuriya KAAS, Ralhan R. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco - a review. J Oral Pathol Med 2007; 36:63-77. [PMID: 17238967 DOI: 10.1111/j.1600-0714.2007.00496.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
While carcinogenicity of smokeless tobacco (ST) to humans is well established the oral lesions that precede development of cancer are less well characterized. The clinical appearances of ST-associated lesions are variable. Epidemiological studies show a strong significant association of risk with chronic daily use but population differences are noted because of various commercial products in use. Morphological features observed are some what different to oral lesions caused by smoking and oral dysplasia in ST-associated lesions is less common. Effects of ST on oral keratinocytes observed in vitro include alterations in cell proliferation, apoptosis and activation of inflammatory markers. Genetic aberrations caused by ST include activation of ras, uncommon in smokers but mutational hot spots in p53 encountered are similar to those in smokers.
Collapse
Affiliation(s)
- K A A S Warnakulasuriya
- Department of Oral Medicine and Pathology, WHO Collaborating Centre for Oral Cancer and Precancer, King's College Dental Institute at Guy's, King's and St Thomas' Hospitals, London, UK.
| | | |
Collapse
|
42
|
Abstract
5-Methylcytosine in DNA is genetically unstable. Methylated CpG (mCpG) sequences frequently undergo mutation resulting in a general depletion of this dinucleotide sequence in mammalian genomes. In human genetic disease- and cancer-relevant genes, mCpG sequences are mutational hotspots. It is an almost universally accepted dogma that these mutations are caused by random deamination of 5-methylcytosines. However, it is plausible that mCpG transitions are not caused simply by spontaneous deamination of 5-methylcytosine in double-stranded DNA but by other processes including, for example, mCpG-specific base modification by endogenous or exogenous mutagens or, alternatively, by secondary factors operating at mCpG sequences and promoting deamination. We also discuss that mCpG sequences are favored targets for specific exogenous mutagens and carcinogens. When adjacent to another pyrimidine, 5-methylcytosine preferentially undergoes sunlight-induced pyrimidine dimer formation. Certain polycyclic aromatic hydrocarbons form guanine adducts and induce G to T transversion mutations with high selectivity at mCpG sequences.
Collapse
Affiliation(s)
- G P Pfeifer
- Division of Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
| |
Collapse
|
43
|
Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15:158-61. [PMID: 16434604 DOI: 10.1158/1055-9965.epi-05-0622] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Lung cancer is a multigenic disease where one variant single nucleotide polymorphism may have only a modest independent effect on the disease phenotype, yet in aggregate, multiple biologically relevant single nucleotide polymorphisms may provide a more accurate representation of risk. Polymorphisms in members of the p53 family, such as p53 and p73, that have a functional relevance would be predicted to contribute to the disease phenotype. In this analysis, we used genotype data from 863 lung cancer cases and 852 healthy controls to test for multigenetic effects of polymorphisms at p53 exon 4, introns 3 and 6, and at p73 exon 2. All individuals in this analysis were self-reported non-Hispanic Caucasians. When the p73 and p53 variant alleles were combined and analyzed as a continuous variable, there was a 13% increase [odds ratios (OR), 1.13; 95% confidence intervals (CI), 1.05-1.21] in lung cancer risk for each additional variant allele. Furthermore, when the number of variant alleles was categorized into three groups (zero, one to three, and four or more variants), there was evidence of a gene-dosage effect with increased risks for individuals with one to three variants (OR, 1.30; 95% CI, 1.05-1.61) and four or more variants (OR, 1.78; 95% CI, 1.23-2.56). When the data were stratified by smoking status, an increased risk for lung cancer was evident only in current (OR, 2.32; 95% CI, 1.25-4.33) and former smokers (OR, 1.73; 95% CI, 1.02-2.94) with four or more variants. Younger individuals with four or more variants were also at a significantly increased risk for lung cancer (OR, 3.15; 95% CI, 1.62-6.12). This study provides support for the multigenetic effects of variant alleles from p53 exon 4, and introns 3 and 6, and p73, and their interplay with smoking, resulting in a significantly increased risk for lung cancer in this Caucasian population.
Collapse
Affiliation(s)
- Matthew B Schabath
- Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
| | | | | | | | | | | |
Collapse
|
44
|
Yu Z, Loehr CV, Fischer KA, Louderback MA, Krueger SK, Dashwood RH, Kerkvliet NI, Pereira CB, Jennings-Gee JE, Dance ST, Miller MS, Bailey GS, Williams DE. In utero Exposure of Mice to Dibenzo[a,l]Pyrene Produces Lymphoma in the Offspring: Role of the Aryl Hydrocarbon Receptor. Cancer Res 2006; 66:755-62. [PMID: 16424006 DOI: 10.1158/0008-5472.can-05-3390] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Lymphoma and leukemia are the most common cancers in children and young adults; in utero carcinogen exposure may contribute to the etiology of these cancers. A polycyclic aromatic hydrocarbon (PAH), dibenzo[a,l]pyrene (DBP), was given to pregnant mice (15 mg/kg body weight, gavage) on gestation day 17. Significant mortalities in offspring, beginning at 12 weeks of age, were observed due to an aggressive T-cell lymphoblastic lymphoma. Lymphocytes invaded numerous tissues. All mice surviving 10 months, exposed in utero to DBP, exhibited lung tumors; some mice also had liver tumors. To assess the role of the aryl hydrocarbon receptor (AHR) in DBP transplacental cancer, B6129SF1/J (AHR(b-1/d), responsive) mice were crossed with strain 129S1/SvIm (AHR(d/d), nonresponsive) to determine the effect of maternal and fetal AHR status on carcinogenesis. Offspring born to nonresponsive mothers had greater susceptibility to lymphoma, irrespective of offspring phenotype. However, when the mother was responsive, an AHR-responsive phenotype in offspring increased mortality by 2-fold. In DBP-induced lymphomas, no evidence was found for TP53, beta-catenin, or Ki-ras mutations but lung adenomas of mice surviving to 10 months of age had mutations in Ki-ras codons 12 and 13. Lung adenomas exhibited a 50% decrease and a 35-fold increase in expression of Rb and p19/ARF mRNA, respectively. This is the first demonstration that transplacental exposure to an environmental PAH can induce a highly aggressive lymphoma in mice and raises the possibility that PAH exposures to pregnant women could contribute to similar cancers in children and young adults.
Collapse
Affiliation(s)
- Zhen Yu
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331-7301, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Gao WM, Romkes M, Siegfried JM, Luketich JD, Keohavong P. Polymorphisms in DNA repair genesXPD andXRCC1 and p53 mutations in lung carcinomas of never-smokers. Mol Carcinog 2006; 45:828-32. [PMID: 16865671 DOI: 10.1002/mc.20208] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The etiology of lung cancer in population with little or no tobacco exposure is not well understood. Individual genetic susceptibility factors have been suggested to contribute to lung cancer risk in this population. Mutations in the p53 tumor suppressor gene are implicated in the development of lung cancer as they are frequently found in lung tumors from both smokers and never-smokers. In order to determine whether genetic polymorphisms affecting DNA repair capacity modulate p53 mutations in lung tumors from never-smokers, we compared p53 mutations with genotypes of XPD 312, XPD 751, and XRCC1 399 in lung tumors from 43 lifetime never-smokers. p53 mutations were identified in 10 (23%) cases and consisted mostly of G/C to A/T transitions. No statistically significant association was found between p53 mutations and genotypes of XPD 312 or XPD 751. However, patients with the XRCC1 399 Gln allele, that results in a lower base excision repair capacity, were more likely to have p53 mutations, compared with patients the wild-type Arg allele (P = 0.03). In addition, the p53 mutation frequency increased with an increasing number of combined genotypes associated with a lower DNA repair capacity of XPD 312, XPD 751, and XRCC1 399 (P = 0.02). These results suggest that individuals who never smoked and had XRCC1 399 Gln allele may be at a greater risk of p53 mutations, especially if combined with the genotypes of XPD 312 and XPD 751 that may result in a lower DNA repair capacity.
Collapse
Affiliation(s)
- Wei-Min Gao
- Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA
| | | | | | | | | |
Collapse
|
46
|
Vineis P, Husgafvel-Pursiainen K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 2005; 26:1846-55. [PMID: 16123121 DOI: 10.1093/carcin/bgi216] [Citation(s) in RCA: 204] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Large cohort studies in the U.S. and in Europe suggest that air pollution may increase lung cancer risk. Biomarkers can be useful to understand the mechanisms and to characterize high-risk groups. Here we describe biomarkers of exposure, in particular DNA adducts as well as markers of early damage, including mutagenicity, other endpoints of genotoxicity and molecular biomarkers of cancer. Several studies found an association between external measures of exposure to air pollution and increased levels of DNA adducts, with an apparent levelling-off of the dose-response relationship. Also, numerous experimental studies in vitro and in vivo have provided unambiguous evidence for genotoxicity of air pollution. In addition, due to the organic extracts of particulate matter [especially various polycyclic aromatic hydrocarbon (PAH) compounds], particulate air pollution induces oxidative damage to DNA. The experimental work, combined with the data on frequent oxidative DNA damage in lymphocytes in people exposed to urban air pollution, suggests 8-oxo-dG as one of the important promutagenic lesions. Lung cancer develops through a series of progressive pathological changes occurring in the respiratory epithelium. Molecular alterations such as loss of heterozygosity, gene mutations and aberrant gene promoter methylation have emerged as potentially promising molecular biomarkers of lung carcinogenesis. Data from such studies relevant for emissions rich in PAHs are also summarized, although the exposure circumstances are not directly relevant to outdoor air pollution, in order to shed light on potential mechanisms of air pollution-related carcinogenesis.
Collapse
Affiliation(s)
- Paolo Vineis
- Department of Epidemiology and Public Health, Imperial College of Science, Technology and Medicine, Norfolk Place, London, UK.
| | | |
Collapse
|
47
|
Rajesh M, Wang G, Jones R, Tretyakova N. Stable isotope labeling-mass spectrometry analysis of methyl- and pyridyloxobutyl-guanine adducts of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in p53-derived DNA sequences. Biochemistry 2005; 44:2197-207. [PMID: 15697245 DOI: 10.1021/bi0480032] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The p53 tumor suppressor gene is a primary target in smoking-induced lung cancer. Interestingly, p53 mutations observed in lung tumors of smokers are concentrated at guanine bases within endogenously methylated (Me)CG dinucleotides, e.g., codons 157, 158, 245, 248, and 273 ((Me)C = 5-methylcytosine). One possible mechanism for the increased mutagenesis at these sites involves targeted binding of metabolically activated tobacco carcinogens to (Me)CG sequences. In the present work, a stable isotope labeling HPLC-ESI(+)-MS/MS approach was employed to analyze the formation of guanine lesions induced by the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) within DNA duplexes representing p53 mutational "hot spots" and surrounding sequences. Synthetic DNA duplexes containing p53 codons 153-159, 243-250, and 269-275 were prepared, where (Me)C was incorporated at all physiologically methylated CG sites. In each duplex, one of the guanine bases was replaced with [1,7,NH(2)-(15)N(3)-2-(13)C]-guanine, which served as an isotope "tag" to enable specific quantification of guanine lesions originating from that position. After incubation with NNK diazohydroxides, HPLC-ESI(+)-MS/MS analysis was used to determine the yields of NNK adducts at the isotopically labeled guanine and at unlabeled guanine bases elsewhere in the sequence. We found that N7-methyl-2'-deoxyguanosine and N7-[4-oxo-4-(3-pyridyl)but-1-yl]guanine lesions were overproduced at the 3'-guanine bases within polypurine runs, while the formation of O(6)-methyl-2'-deoxyguanosine and O(6)-[4-oxo-4-(3-pyridyl)but-1-yl]-2'-deoxyguanosine adducts was specifically preferred at the 3'-guanine base of 5'-GG and 5'-GGG sequences. In contrast, the presence of 5'-neighboring (Me)C inhibited O(6)-guanine adduct formation. These results indicate that the N7- and O(6)-guanine adducts of NNK are not overproduced at the endogenously methylated CG dinucleotides within the p53 tumor suppressor gene, suggesting that factors other than NNK adduct formation are responsible for mutagenesis at these sites.
Collapse
Affiliation(s)
- Mathur Rajesh
- University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
| | | | | | | |
Collapse
|
48
|
Bitton A, Neuman MD, Barnoya J, Glantz SA. The p53 tumour suppressor gene and the tobacco industry: research, debate, and conflict of interest. Lancet 2005; 365:531-40. [PMID: 15705463 DOI: 10.1016/s0140-6736(05)17871-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Mutations in the p53 tumour suppressor gene lead to uncontrolled cell division and are found in over 50% of all human tumours, including 60% of lung cancers. Research published in 1996 by Denissenko and colleagues demonstrated patterned in-vitro mutagenic effects on p53 of benzo[a]pyrene, a carcinogen present in tobacco smoke. We investigated the tobacco industry's response to p53 research linking smoking to cancer. We searched online tobacco document archives, including the Legacy Tobacco Documents Library and Tobacco Documents Online, and archives maintained by tobacco companies such as Philip Morris and R J Reynolds. Documents were also obtained from the British American Tobacco Company depository in Guildford, UK. Informal correspondence was carried out with scientists, lawyers, and tobacco control experts in the USA and Europe. We found that executives and scientists at the highest levels of the tobacco industry anticipated and carefully monitored p53 research. The tobacco industry's own scientists conducted research which appeared to cast doubt on the link between smoking and p53 mutations. Researchers and a journal editor with tobacco industry ties participated in the publication of this research in a peer-reviewed journal without clear disclosure of their tobacco industry links. Tobacco industry responses to research linking smoking to carcinogenic p53 mutations mirror prior industry efforts to challenge the science linking smoking and lung cancer. The extent of tobacco industry involvement in p53 research and the potential conflict of interest discussed here demonstrate the need for consistent standards for the disclosure and evaluation of such potential conflicts in biomedical research.
Collapse
Affiliation(s)
- Asaf Bitton
- Center for Tobacco Control Research and Education, University of California, San Francisco, CA 94143, USA
| | | | | | | |
Collapse
|
49
|
Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC. Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma. Clin Cancer Res 2005. [DOI: 10.1158/1078-0432.232.11.1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Abstract
Purpose: Many studies have highlighted the aberrant expression and prognostic significance of individual proteins in either the Rb (particularly cyclin D1, p16INK4A, and pRb) or the p53 (p53 and p21Waf1) pathways in non–small cell lung cancer. We hypothesize that cumulative abnormalities within each and between these pathways would have significant prognostic potential regarding survival.
Experimental Design: Our study population consisted of 106 consecutive surgically resected cases of predominantly early-stage non–small cell lung cancer from the National Cancer Institute-Mayo Clinic series, and assessment of proteins involved both immunohistochemical (cyclin D1, p21Waf1, pRb, p16INK4A, and p53) and mutational analysis (p53) in relationship to staging and survival.
Results: Cyclin D1 overexpression was noted in 48% of the tumors, p16INK4A negative in 53%, pRb negative in 17%, p53 immunopositive in 50%, p53 mutation frequency in 48%, and p21Waf1 overexpression in 47%, none with prognostic significance. Cyclin D1 overexpression in pRb-negative tumors revealed a significantly worse prognosis with a mean survival of 2.3 years (P = 0.004). A simultaneous p53 mutation dramatically reduced the mean survival time to 0.9 years (P = 0.007). Cyclin D1 overexpression with either a p53 mutation or a p53 overexpression was also associated with a significantly poorer prognosis (P = 0.0033 and 0.0063, respectively).
Conclusions: Some cumulative abnormalities in the Rb and p53 pathways (e.g., cyclin D1 overexpression and p53 mutations) significantly cooperate to predict a poor prognosis; however, the complexity of the cell cycle protein interaction in any given tumor warrants caution in interpreting survival results when specific protein abnormalities are taken in isolation.
Collapse
Affiliation(s)
- Louise Burke
- 1Department of Pathology, Cork University Hospital, Cork, Ireland
| | - Douglas B. Flieder
- 2Department of Pathology, New York Hospital/Cornell University Medical College, New York, New York
| | - Donald G. Guinee
- 3Department of Pathology, Virginia Mason Clinic, Seattle, Washington
| | - Elizabeth Brambilla
- 4Service de Pathologie Cellulaire, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
| | | | - William P. Bennett
- 9Division of Human Genetics, City of Hope National Medical Center and Beckman Research Institute, Duarte, California
| | - Raymond T. Jones
- 10Department of Pathology, University of Maryland, Baltimore, Maryland
| | - Andrew Borkowski
- 10Department of Pathology, University of Maryland, Baltimore, Maryland
| | | | | | - Victor Trastek
- 12Department of Thoracic Surgery, Mayo Clinic Scottsdale, Scottsdale, Arizona; Departments of
| | | | | | - David Midthun
- 15Thoracic Disease Division, Mayo Clinic, Rochester, Minnesota; and
| | - James R. Jett
- 15Thoracic Disease Division, Mayo Clinic, Rochester, Minnesota; and
| | | | - William D. Travis
- 16Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington, District of Columbia
| | - Curtis C. Harris
- 8Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland
| |
Collapse
|
50
|
DeMarini DM. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat Res 2004; 567:447-74. [PMID: 15572290 DOI: 10.1016/j.mrrev.2004.02.001] [Citation(s) in RCA: 355] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2004] [Revised: 02/11/2004] [Accepted: 02/17/2004] [Indexed: 12/29/2022]
Abstract
This report reviews the literature on the genotoxicity of mainstream tobacco smoke and cigarette smoke condensate (CSC) published since 1985. CSC is genotoxic in nearly all systems in which it has been tested, with the base/neutral fractions being the most mutagenic. In rodents, cigarette smoke induces sister chromatid exchanges (SCEs) and micronuclei in bone marrow and lung cells. In humans, newborns of smoking mothers have elevated frequencies of HPRT mutants, translocations, and DNA strand breaks. Sperm of smokers have elevated frequencies of aneuploidy, DNA adducts, strand breaks, and oxidative damage. Smoking also produces mutagenic cervical mucus, micronuclei in cervical epithelial cells, and genotoxic amniotic fluid. These data suggest that tobacco smoke may be a human germ-cell mutagen. Tobacco smoke produces mutagenic urine, and it is a human somatic-cell mutagen, producing HPRT mutations, SCEs, microsatellite instability, and DNA damage in a variety of tissues. Of the 11 organ sites at which smoking causes cancer in humans, smoking-associated genotoxic effects have been found in all eight that have been examined thus far: oral/nasal, esophagus, pharynx/larynx, lung, pancreas, myeoloid organs, bladder/ureter, uterine cervix. Lung tumors of smokers contain a high frequency and unique spectrum of TP53 and KRAS mutations, reflective of the PAH (and possibly other) compounds in the smoke. Further studies are needed to clarify the modulation of the genotoxicity of tobacco smoke by various genetic polymorphisms. These data support a model of tobacco smoke carcinogenesis in which the components of tobacco smoke induce mutations that accumulate in a field of tissue that, through selection, drive the carcinogenic process. Most of the data reviewed here are from studies of human smokers. Thus, their relevance to humans cannot be denied, and their explanatory powers not easily dismissed. Tobacco smoke is now the most extreme example of a systemic human mutagen.
Collapse
Affiliation(s)
- David M DeMarini
- Environmental Carcinogenesis Division, National Health and Environmental Effects Research Laboratory, US Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA.
| |
Collapse
|